THERAPY DOSSIER · th-6a86cc7f8f7e

Mature naive syngeneic splenic B lymphocytes

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30997843 ↗2019Reported benefit

Intraparenchymal Application of Mature B Lymphocytes Improves Structural and Functional Outcome after Contusion Traumatic Brain Injury.

MouseTBIControlled cortical impactC57BL/6maleintraparenchymal injection at the lesion site2 x 10^(exponent not recoverable from source encoding) matu…injected immediately before controlled cortical impact

Model: Controlled cortical impact (CCI) contusion traumatic brain injury

Mice given intraparenchymal B cells showed significantly improved post-injury rotarod, Y maze and Morris water maze performance compared with saline or T cell controls, and lesion volume was reduced by 40% at 35 days post-injury, with decreased astrogliosis and microglial activation. Sham groups pe…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…